PCM
IOVA icon

Prelude Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Prelude Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,000
Closed -$97.6K – 1423
2023
Q4 		$97.6K Buy
+12,000
New +$62.8K 0.01% 1030
2023
Q2 		– Sell
-46,435
Closed -$284K – 1235
2023
Q1 		$284K Buy
+46,435
New +$320K 0.02% 668
2021
Q1 		– Sell
-4,481
Closed -$208K – 1679
2020
Q4 		$208K Sell
4,481
-5,325
-54% -$211K 0.01% 1097
2020
Q3 		$323K Sell
9,806
-1,852
-16% -$56.8K 0.02% 536
2020
Q2 		$320K Buy
11,658
+3,559
+44% +$117K 0.02% 602
2020
Q1 		$242K Sell
8,099
-6,669
-45% -$177K 0.02% 414
2019
Q4 		$409K Buy
14,768
+75
+0.5% +$1.71K 0.02% 612
2019
Q3 		$267K Buy
14,693
+14,633
+24,388% +$324K 0.01% 684
2019
Q2 		$1K Buy
+60
New +$904 ﹤0.01% 1593
2018
Q4 		– Sell
-5,500
Closed -$62K – 1964
2018
Q3 		$62K Sell
5,500
-2,500
-31% -$35.5K ﹤0.01% 1076
2018
Q2 		$102K Sell
8,000
-2,500
-24% -$36.5K 0.01% 909
2018
Q1 		$177K Buy
10,500
+500
+5% +$7.57K 0.01% 708
2017
Q4 		$80K Buy
10,000
+2,500
+33% +$20.1K 0.01% 843
2017
Q3 		$58K Sell
7,500
-32,034
-81% -$203K 0.01% 1055
2017
Q2 		$291K Sell
39,534
-300
-0.8% -$1.91K 0.03% 466
2017
Q1 		$297K Buy
39,834
+15,116
+61% +$111K 0.03% 439
2016
Q4 		$172K Buy
24,718
+4,773
+24% +$32.8K 0.02% 638
2016
Q3 		$164K Buy
19,945
+18,945
+1,895% +$160K 0.02% 629
2016
Q2 		$8K Sell
1,000
-15,500
-94% -$97.3K ﹤0.01% 1410
2016
Q1 		$84K Buy
+16,500
New +$90.3K 0.01% 815
2015
Q3 		– Sell
-3,700
Closed -$34K – 1622
2015
Q2 		$34K Buy
3,700
+2,500
+208% +$27.9K ﹤0.01% 1244
2015
Q1 		$15K Buy
+1,200
New +$13.5K ﹤0.01% 1789

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Prelude Capital Management's IOVA Position: Q1 2024 in Review

Prelude Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 12,000 shares — an estimated $97.6K sold.

Prelude Capital Management first reported a position in IOVA in Q1 2015 and held it in 22 quarters. The position peaked at $409K in Q4 2019. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

  • Prelude Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Prelude Capital Management sold 12,000 Iovance Biotherapeutics shares in Q1 2024, an estimated $97.6K.
  • Prelude Capital Management first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 22 quarters.
  • Prelude Capital Management's Iovance Biotherapeutics position peaked at $409K in Q4 2019.
  • 273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.